adopted formalized screening programs for distress. 25 In response, a quality improvement (QI) project was developed to improve care through identifying and addressing distress in HNC medical oncology patients. Specifically, a microsystem-based theory was
Search Results
Addressing Distress in Patients With Head and Neck Cancers: A Mental Health Quality Improvement Project
Natalie Riblet, Karen Skalla, Auden McClure, Karen Homa, Alison Luciano, and Thomas H. Davis
A Prospective Six Sigma Quality Improvement Trial to Optimize Universal Screening for Genetic Syndrome Among Patients With Young-Onset Colorectal Cancer
Sean Dineen, Patrick M. Lynch, Miguel A. Rodriguez-Bigas, Sarah Bannon, Melissa Taggart, Colleen Reeves, Cathy Modaro, Michael Overman, George J. Chang, John M. Skibber, and Y. Nancy You
improvement conceptual framework, would improve adherence to NCCN Guidelines and optimize tumor-based screening for LS in young adults with CRC. Methods Study Design and Conceptual Framework The aim of this prospective quality improvement trial was
Development and Implementation of a Medical Oncology Quality Improvement Tool for a Regional Community Oncology Network: The Fox Chase Cancer Center Partners Initiative
Margaret A. O'Grady, Elena Gitelson, Ramona F. Swaby, Lori J. Goldstein, Elaine Sein, Patricia Keeley, Bonnie Miller, Tianyu Li, Alan Weinstein, and Steven J. Cohen
Fox Chase Cancer Center Partners (FCCCP) is a community hospital/academic partnership consisting of 25 hospitals in the Delaware Valley. Originally created in 1986, FCCCP promotes quality community cancer care through education, quality assurance, and access to clinical trial research. An important aspect of quality assurance is a yearly medical oncology audit that benchmarks quality indicators and guidelines and provides a roadmap for quality improvement initiatives in the community oncology clinical office setting. Each year, the FCCCP team and the Partner Medical Oncologists build disease site- and stage-specific indicators based on National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Concordance with multiple indicators is assessed on 20 charts from each community practice. A report for each FCCCP medical oncology practice summarizes documentation, screening recommendations, new drug use, and research trends in a particular disease site. Descriptive statistics reflect indicators met, number of new cases seen per year, number of disease site cases from tumor registry information, and clinical trial accrual total. Education and documentation tools are provided to physicians and oncology office nursing staff. The FCCCP Clinical Operations Team, consisting of medical oncologists and oncology-certified nurses, has conducted quality audits in medical oncology offices for 7 years using NCCN-derived indicators. Successful audits comprising gastric, colorectal, and breast cancer have been the focus of recent evaluations. For the 2005 stage II/III breast cancer evaluation, mean compliance per parameter was 88%, with 15 of 16 practices achieving mean compliance greater than 80%. A large-scale quality assurance audit in a community cancer partner network is feasible. Recent evaluation of localized breast cancer shows high compliance with guidelines and identifies areas for focused education. Partnership between academic and community oncologists produces a quality review process that is broadly applicable and adaptable to changing medical knowledge.
Quality Improvement in Breast Cancer Project: Compliance With Antiresorptive Agents and Changing Patterns of Drug Use
Charles P. Borden, Charles L. Shapiro, Maria Teresa Ramirez, Linda Kotur, and William Farrar
First, the results and analysis were shared with the breast cancer disease-specific committee to increase awareness and gather ideas for improving the process. As is often the case with quality improvement projects, the solutions were multifold, and
QIM19-133: Assessing and Reducing FDG PET/CT Radiotracer Infiltrations: Lessons in Quality Improvement Sustainability
Jackson W. Kiser, James Crowley, Thad Benefield, Ronald Lattanze, Steve Perrin, Kelley Ryan, and Josh Knowland
(QC) efforts to ensure accuracy of the administered dose, there is no routine QC method that confirms complete delivery of the dose into the patient's circulation. 5 technologists in our center participated in a quality improvement project that reduced
QIM19-122: Quality Improvement Initiatives in the Second Year of an Adolescent and Young Adult Oncology Clinic
Heather Bowers, Kerri Susko, Aniket Saha, and Elizabeth Cull
quality improvement initiatives were created to address these issues. Methods: The study assessed patients actively under treatment between ages 15–39 from September 1, 2016 to September 1, 2018 that were seen in the AYA clinic. Starting in year 2
QIM19-139: Reflex Testing of Oncotype DX Recurrence Score: A Single Institution Review of a Quality Improvement Protocol
Mara A. Piltin, Kathryn Eckert, Margaret Wight, Alan J. Shienbaum, Jeanine Chiffarano, Trina A. Poretta, Tamara A. LaCouture, Monica N. Khattak, Michele E. Gaguski, Alyssa Imperatore, Sruti Golthi, and Kahyun Yoon-Flannery
subgroups of tumors. Our institution identified the time to assay result as a quality improvement opportunity. We instituted a protocol to have a reflex testing of Oncotype DX based on certain criteria to decrease time to assay results and ultimately time to
QIM19-130: Quality Improvement Project to Standardize a Prehabilitation Pathway for Patients With Esophageal Cancer Receiving Neoadjuvant Chemoradiation
Ashley E. Glode, S. Lindsey Davis, Supriya K. Jain, Megan D. Marsh, Lisa J. Wingrove, Tracey E. Schefter, Karyn Goodman, Lindel C.K. Dewberry, Martin D. McCarter, Laura Melton, Michelle Bunch, William T. Purcell, and Stephen Leong
tolerate, and they may be unable to receive full dose therapy without treatment dose reductions and delays. Methods: We conducted a quality improvement (QI) project, STRENGTH (Seeking to Reactivate Esophageal and Gastric Treatment Health), to implement
QIM19-138: Care Coordination Between Prescribers and the Specialty Pharmacy—Qualitative Insights Into Designing a Quality Improvement Program for Multisite Community Oncology Practices
Stacey W. MucCullough, David Blaisdell, Jonathan K. Kish, Pat Farmer, JaLyna Laney, Tom Valuck, Natalie Dickson, Johnetta Blakely, Dianna Shipley, Jesus Berdeja, Gregg Shepard, Bertrand M. Anz III, Carolyn Kelsey, Jack Taylor, Chadi Nabhan, Jeffrey F. Patton, and Annette Powers
/AC); care coordination (CC); disease management for MM (DMMM); patient education (PE); medication management (MedMgmt); and data and quality improvement (DQI). Results: Five providers treating 304 MM patients from January 2016 through April 2018 identified
QIM20-128: Baseline Assessment of Oncology Providers’ Quality Improvement Knowledge in a Multi-Institutional Breast Cancer Quality Improvement Collaborative
Lindsey Kreutzer, Ashley Byerly, Eileen Ngo, Julie K. Johnson, Karl Y. Bilimoria, and Anthony D. Yang
Background: The Northwestern Medicine Breast Cancer Quality Improvement Collaborative (NM BCQIC) is a novel health system-wide QI collaborative of 5 hospitals developed to equip providers with the knowledge and skills to identify and improve upon
